Merck has received Patents in India for Obesity and Dyslipidemia Drugs

US-based Merck has received patent approval for two of its upcoming drugs for  dyslipidemia and obesity from the Indian Patent Office. The two newly patented drugs that are in the final stages of trial and are yet to receive the Drug Controller General of India’s (DCGI) approval.

 

Till now, Merck has only patent for its anti-diabetic drug called Januvia a 770 million product.

 

MSD Pharma is a wholly owned subsidiary of Merck & Co in India. Its director (marketing) Sanjiv Navangul said, “We have received patent approval for two more drugs in India which are in advanced Phase III trials. We soon expect to launch them here. However, we will have a competitive and right pricing for all our patented drugs based on comprehensive research.”